AbbVie reported on Tuesday that it will purchase Allergan in an arrangement esteemed at about $63 billion, a 45% premium on Allergan’s latest shutting stock cost. The proposed M&A will be one of the biggest medicinal services mergers of the year and unite a portfolio that incorporates AbbVie’s Humira, the world’s smash hit medication, and…